MMP7 and breast angiosarcoma: The variable cut-offs between studies and differences in the performance of the individual kits limit the use of MMP-7.17,18 Ideally, clinically relevant biomarkers should approach a 100% negative predictive value for diagnosing BA to be translated to clinical practice.